List of Tables
Table 1-1: Exchange Rate Fluctuations, 2018-2022
Table 1-1a: Global In Vitro Diagnostic Sales by Product Market, 2022-2027 ($ million) (Clinical Chemistry; Immunoassays- non isotopic: Infectious disease, Other immunoassays, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology - Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry) and COVID-19 Dx 2022
Table 1-1b: Global In Vitro Diagnostic Products, Markets of Interest, 2022-2027 (Sequencing - clinical, Prenatal Test Services, DTC Genetic Testing, Flow Cytometry, Drugs of Abuse: Employment (non-IVD), and Drugs of Abuse: Criminal)
Table 2-1a: Global In Vitro Diagnostic Sales by Product Market, 2022-2027 ($ million) (Clinical Chemistry; Immunoassays- non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology - Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry) and COVID-19 Dx 2022
Table 2-1b: Global In Vitro Diagnostic Products, Markets of Interest, 2022-2027 (Sequencing - clinical, Prenatal Test Services, DTC Genetic Testing, Flow Cytometry, Drugs of Abuse: Employment (non-IVD), and Drugs of Abuse: Criminal)
Table 2-2: Clinical Diagnostic Revenues of Selected Top 20 IVD Companies*, 2021 and estimated 2022 ($ million)
Table 2-3: Revenues of Selected Top 20 Niche Players, 2021 and estimated 2022 ($ million, estimated) *
Table 2-4: Selected IVD Mergers and Acquisitions 2019-2022 (first half)
Table 2-5: Selected IVD Partnerships/Collaborations/Alliance Agreements 2016-2019
Table 2-6: Selected Test Services, Sales 2017-2021 ($ millions, estimated where applicable)
Table 2-7: Global Lab Market Segmentation, 2021 ($ billions)
Table 2-8: Revenues for a Selection of U.S.-based Reference Labs, 2017-2021 ($ million, estimated)
Table 2-9: Estimated Clinical Test Volume by Select Independent Laboratory, 2021 (millions of units)
Table 2-10: Estimated COVID-19 Test Volume by Select Independent Laboratory, 2021 (millions of units)
Table 2-11: COVID-19 Market Estimates by Segment (Immunoassay, Molecular, Rapid - POC), 2022 ($ millions)
Table 3-1: Elderly Support Ratio in Various Countries (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
Table 3-2: Age Under 15 and Over 65, by Continent (Africa, L. America/Caribbean, Asia, Oceania, N. America, Europe, World) 2020
Table 3-3: WHO Model List of Essential In Vitro Diagnostics (EDL)
Table 3-4: Individual EUAs for Molecular Tests for SARS-CoV-2
Table 3-5: Authorized Molecular-Based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2
Table 3-6: Individual EUAs for Antigen Diagnostic Tests for SARS-CoV-2
Table 3-6: Individual EUAs for Serology Tests for SARS-CoV-2
Table 3-7: Individual EUAs For IVDs for Management of COVID-19 Patients
Table 3-8: Market Potential by Total Population, and Percent Urban 2020 (China, India, United States, Brazil, Russia, Mexico, Turkey, S. Korea, S. Africa, Vietnam, Poland, Saudi Arabia, Canada, Colombia, Ukraine, Egypt, Malaysia, Peru, and Chile)
Table 3-9: Global In Vitro Diagnostic Market; Major Country/Region Markets, 2022 and 2027 ($ millions) (United States, EU 15/W. Europe, Japan, China, Canada, India, Eastern Europe, Brazil, Peru, Mexico, Saudi Arabia, Turkey, UAE, Vietnam, Russia, South Africa, South Korea, Australia, ROW)
Table 3-10: Global In Vitro Diagnostic Market; Regional Markets, 2022 and 2027 ($ millions) (North America, Europe, Asia Pacific, Latin America, ROW)
Table 3-11: Global In Vitro Diagnostic Market - YOY Growth 2021-2022
Table 3-12: Global In Vitro Diagnostic Market; Regional Markets, 2021-2022 YOY Growth (North America, Europe, Asia Pacific, Latin America, ROW)
Table 3-13: United States IVD Market Share by Segment, 2022 (%) (Clinical Chemistry, Microbiology ID/AST, Microbiology Molecular, POC Diabetes, POC Other, Immunoassay Infectious Disease, Immunoassay Other, Nucleic Acid Assays, Coagulation, Histology, Hematology, Blood Grouping, Others), Total Market Value $54,033 million; Clinical Sequencing $2,916 million ($ millions)
Table 3-14: Proposed Clinical Diagnostic Laboratory Test Rates, 2020-2025
Table 3-15: Economic Indicators (GDP Growth, Inflation Growth) by Select European Country (Germany, France, Italy, Spain), 2020-2023 (%)
Table 3-16: Western European IVD Market by Country, 2022 ($ millions, estimated) (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK)
Table 3-17: IVD Market Per Capita, Europe, 2021/2022 Estimates (Switzerland, Germany, Netherlands, Sweden, France, Slovenia, United Kingdom, Italy, Spain, Slovakia, Greece, Croatia, Czech Republic, Hungary, Poland, Romania, Bulgaria, Russia, Ukraine)
Table 3-18: Japan IVD Market by Segment, 2022 (%) (Clinical Chemistry, Microbiology ID/AST, Microbiology Molecular, POC Diabetes, POC Other, Immunoassay Infectious Disease, Immunoassay Other, Coagulation, Histology, Hematology, Others)
Table 3-19: Eastern European IVD Market by Country, 2022 ($ millions) (Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia, Slovenia, Ukraine, Other)
Table 3-20: China IVD Market by Segment, 2022 (%) (Clinical Chemistry, Microbiology ID/AST, Microbiology Molecular, POC Diabetes, POC Other, Immunoassay Infectious Disease, Immunoassay Other, Coagulation, Histology, Hematology, Others)
Table 3-21: Total Midyear Population by Broad Age Group: China (million persons), 2010-2050
Table 3-22: India IVD Market by Segment, 2022 (%) (Clinical Chemistry, Hematology, Coagulation; Microbiology; POC Diabetes; POC Other; Immunoassay; Histology; Others)
Table 3-23: Asia Pacific IVD Market by Country, 2022 ($ millions) (Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam)
Table 3-24: Brazil IVD Market by Broad Segment, 2022 (%) (Clinical Chemistry, Microbiology, POC Diabetes, POC Other, Immunoassay, Histology, Others)
Table 3-25: Mexico IVD Market by Broad Segment, 2022 (%) (Clinical Chemistry, Microbiology, POC, Immunoassay, Histology, Others)
Table 3-26: IVD Market Opportunity by Country (2022 Market Rank, Country CAGR 2022-2027) (China, Philippines, Brazil, Israel, Malaysia, India, Mexico, Indonesia, Chile, Poland, Saudi Arabia, South Korea, Romania, Colombia, United Arab Emirates, Argentina, Hungary, Vietnam, Iraq, Peru, Japan, France, Turkey, Egypt, Singapore, Luxembourg, Croatia, Jordan, U.S., Germany, United Kingdom, Canada, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Denmark, Ireland, Finland, Iran, Thailand, Venezuela, Italy, Australia, Portugal, Greece, Czech Republic, South Africa, Norway, Bulgaria, Slovakia, Slovenia)
Table 4-1: Key Emerging IVD Markets (Brazil, Russia, India, China, South Korea, Mexico, Turkey, Vietnam) 2017-2022 ($millions)
Table 4-2: Selected Gene Editing / CRISPR Innovations
Table 4-3: Selected Microbiome Test Innovations
Table 4-4: Selected Clinical NGS Platforms on the Market
Table 4-5: Selected AI Market Cleared Tests
Table 4-6: Selected AI Product Initiatives in Development and Collaborations
Table 4-7: Selected AI/Liquid Biopsy Initiatives
Table 4-8: Biotin-free Offerings Currently on the Market
Table 4-9: Global Drug Abuse Statistics
Table 4-10: Selected Opioid Test FDA Approvals
Table 5-1 Professional POC Test Sales by Category, Worldwide 2022 -2027 ($million) (Glucose, Critical Care POC, Fertility, Infectious Diseases, Cardiac Markers, Cholesterol, Coagulation, HbA1c POC, Hematology, Fecal Occult Blood, Drugs of Abuse, Others)
Table 5-2: Selected Professional POC Test Innovations (excluding COVID-19 testing)
Table 5-3: POC Self-Test Sales by Category, Worldwide, 2022-2027($million) (Glucose, Self; Glucose, Continuous; Pregnancy; Coagulation; Fecal Occult Blood; Drugs of Abuse; H. pylori; HIV; Cholesterol; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
Table 5-4: Home Collection Test Market*, 2022 and 2027 ($million), CAGR 2022-2027
Table 5-5: Home Collection Test Kit Market by Category, Worldwide, 2022(% Estimated Share)
Table 5-6: Selected Molecular Tests EUAs for Home Collection SARS-CoV-2 Tests
Table 5-7: POC Pregnancy and Fertility Test Market Distribution by End User, 2022 (%) (OTC, PRO)
Table 5-8: Pregnancy/Fertility POC Test Sales Distribution by Global Region, 2022 (United States, Europe, Japan, RoW)
Table 5-9: Selected POC Colon Cancer Tests
Table 5-10: Colon Cancer POC Test Sales Distribution by Global Region, 2022 (United States, Europe, Japan, RoW)
Table 5-11: Lipid POC Test Sales Distribution by Global Region, 2022 (United States, Europe, Japan, RoW)
Table 5-12: POC Drugs of Abuse Test Sales Distribution by Setting, 2022 (Employment Screening, Criminal Justice, Critical Care - Traditional POC)
Table 5-13: Drugs of Abuse Tests on the Market
Table 5-14: Innovations in Molecular POC Infectious Disease Diagnostics
Table 5-15: Innovations in Molecular POC Infectious Disease Diagnostics
Table 5-16: Infectious Disease POC Test Demand by Type, 2022 (Influenza, HIV, STD, Hepatitis, Malaria, C.Difficile, E.coli, H.pylori, Home Test/OTC, Others)
Table 5-17: Infectious Disease POC Test Sales Distribution by Global Region, 2022 (United States, Europe, Japan, RoW)
Table 5-18: Glucose POC Test Sales Distribution by Global Region, 2022 (United States, Europe, Japan, RoW)
Table 5-19: Selected Apps and Glucose Management IT
Table 5-20: Global Diabetes Sales by Test Category, 2022-2027 (Glucose, OTC; Glucose, professional; Glucose, continuous; HbA1c, POC; TOTAL; HbA1c, Lab) ($ millions)
Table 5-21: POC Test Revenues of Selected IVD Glucose Companies, 2022 ($ million, estimated)
Table 5-22: Selected Glucose Self-Test Meter Innovations
Table 5-23: Selected Noninvasive Glucose Monitoring Devices
Table 5-24: Selected Continuous Blood Glucose System Developments
Table 5-25: Selected Innovations in Hospital-based Glucose Monitoring
Table 5-26: Global HbA1c Test Sales Market and Distribution by Setting, 2022-2027 ($ millions) (HbA1c POC, HbA1c Lab)
Table 5-27: Selected POC HbA1c Devices
Table 5-28: Selected POC Diabetes Monitoring Tests
Table 5-29: POC Test Revenues of Selected IVD Companies, 2022 ($ million, estimated)
Table 6-1: Selected Analytes for the Core Lab
Table 6-2: Global Clinical Chemistry Sales by Test Category, 2022-2027 ($millions) (General Chemistries, Blood Gases, Urinalysis)
Table 6-3: Global Clinical Chemistry Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 6-4: Major Clinical Chemistry Companies (Blood gas/electrolyte, general chemistries, UA)
Table 6-5: Selected Clinical Chemistry Innovations
Table 6-6: Selected Major Whole Blood Chemistry Analyzers
Table 6-7: Blood Gas, Electrolyte and Critical Care Instrument Market by End User, 2022 and 2027 (Lab-based, POC-based) (in $ millions)
Table 6-8: Blood Gas, Electrolyte, and Critical Care Market Leaders including POC, 2022 (percent distribution of total sales)
Table 6-9: Selected Apps, Critical Care and Urinalysis IT Innovations
Table 6-10: UA Market by End User, 2022 and 2027 (Lab-based, POC-based)
Table 6-11: Urinalysis Systems (including POC) Market Leaders, 2022 (percent distribution of total sales) estimated
Table 6-12: Selected Urinalysis Innovations
Table 7-1: Selected Immunoassay Technologies
Table 7-2: Selected Innovation in Mass Spectrometry for Routine Analyses
Table 7-3: Global Lab-based Immunoassay (excluding infectious disease and blood screening) Sales, by Analyte Type, 2022-2027 ($millions) (Cardiac Markers, Tumor Markers, Autoimmune, Diabetes/HbA1c, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic Drugs, Drugs of Abuse, Vitamin D, Total; w/o HbA1c)
Table 7-4: Global Immunoassay (excluding infectious disease and blood screening) Sales Distribution by Region, 2022 (%) (North America, Europe, Japan, Asia Pacific, RoW)
Table 7-5: IVD Quality Control Market (estimated), 2022 ($millions)
Table 7-6: Selected Immunoassay Quality Control Products
Table 7-7: 2021-2022 Revenues of Leading Lab-based Immunoassay Vendors (in millions $), Estimated
Table 7-8: Selected Vitamin D Immunoassays
Table 7-9: Selected Tumor Marker Innovations
Table 7-10: Selected Cardiac Marker Innovations
Table 7-11: Selected Autoimmune Test Innovations
Table 7-12: Selected Arthritis Immunoassay Innovations
Table 7-13: Selected Inflammatory Bowel Disease Test Innovations
Table 7-14: Selected Immunoassays for Transplant Medicine
Table 7-15: Selected Women’s Health Innovations
Table 7-16: Selected Innovations for Alzheimer’s Disease Immunoassays
Table 7-17: Selected Immunoassay Innovations
Table 7-18: Global POC Immunoassay Sales Distribution by Region, 2022 (United States, Europe, Japan, RoW)
Table 7-19: Global POC Immunoassay Test Sales by Test Category, 2022-2027 (millions $) (OTC/Self Tests: Pregnancy/Ovulation, Drugs of Abuse, HIV, H. pylori, Infectious Disease/COVID-19, Other, OTC/Self Total; professional POC: Cardiac Markers, Drugs of Abuse, HbA1c, Pregnancy, Infectious Disease/COVID-19, Other, Professional Total)
Table 7-20: Selected Self-Test Immunoassay Innovations
Table 7-21: Selected POC Test Innovations
Table 7-22: Selected POC Immunoassay Test Platforms
Table 8-1: Common Next Generation Molecular Test Traits
Table 8-2: Selected Molecular Test Sample Preparation and QC Innovations
Table 8-3: Selected Exosome Test Innovations
Table 8-4: Selected Liquid Biopsy Innovations
Table 8-5: Selected IT Innovations in Molecular Diagnostics
Table 8-6: Selected Innovations in Forensic DNA Testing
Table 8-7: Key Molecular Technologies and Major Players
Table 8-8: Selected Molecular Test Platform Innovations
Table 8-9: Molecular Test Revenues of Selected IVD Vendors, 2016-2021, 2022 estimated (in millions $)
Table 8-10: Global Genomic, HLA and Oncology Molecular Test Sales by Type with NIPT 2022-2027 (in millions $)
Table 8-11: Global Molecular Cancer Test Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 8-12: Selected Molecular Tumor Marker Test Innovations
Table 8-13: Most Frequently Requested Genetic Tests
Table 8-14: Global Molecular Thrombophilia Assay Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 8-15: Selected Genomic Tests for Inherited Diseases
Table 8-16: Global Prenatal Test Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 8-17: Selected Prenatal Services Provided
Table 8-18: Selected Molecular Tests for Prenatal Analysis
Table 8-19: Global Molecular HLA Testing Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 8-20: Selected Innovations of Molecular Transplant Diagnostics
Table 9-1: Hematology Analyzer Distribution of Sales by Menu Capability, 2022 estimated
Table 9-2: Lab-based Hematology Sales by Analyte Average Annual Distribution %
Table 9-3: Selected Hematology Image Analysis Innovations, 2014-2022
Table 9-4: Selected Quality Control Hematology FDA Registrations, 2021
Table 9-5: Selected Hematology Innovations, 2014-2022
Table 9-6: Global Laboratory-based Hematology Test and Instrument Market, 2022 and 2027 ($ millions)
Table 9-7: Global Laboratory-based Hematology Test and Instrument Market, by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 9-8: POC Hematology Distribution by Specialty (hematocrit/hemoglobin vs. other routine hematology (WBC, erythrocyte, platelet)
Table 9-9: Selected POC Hemoglobin and Hematocrit Systems
Table 9-10: Selected POC Hematology Analyzer Systems
Table 9-11: Decentralized Hematology Test and Instrument Market, 2022 and 2027($ millions) (Instruments, lab-style; Handheld devices)
Table 9-12: Top Hematology Company Revenues (laboratory and POC), 2022 ($ millions)
Table 9-13: Global Hematology (Laboratory-based and POC) Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 10-1: Major Anticoagulants
Table 10-2: Global D-dimer Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 10-3: Global Coagulation Sales by Segment, 2022-2027 ($millions) (PT/INR Labs, Molecular, Professional POC, Professional Self; D-dimer)
Table 10-4: Global Coagulation Test and Instrument Market by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 10-5: Selected Lab-based Coagulation Innovations
Table 10-6: Related CMS Codes for Reimbursement National Limits, Molecular, 2022
Table 10-7: Global Molecular - Thrombophilia SNP Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 10-8: Selected Molecular Coagulation Test Innovations
Table 10-9: Top Coagulation Company Revenues, Laboratory-based - 2022 ($ millions) est.
Table 10-10: Selected POC Coagulation Test Innovations
Table 10-11: Selected Platelet Activity Test Innovations
Table 10-12: Top Coagulation Company Revenues, POC - 2022 ($ millions) est.
Table 10-13: Major Anticoagulants Uses and Tests
Table 11-1: Selected Companies Developing Faster Identification, Some Also with Antimicrobial Susceptibility/Resistance Tests
Table 11-2: Selected Nucleic Acid Amplification Test and Other Molecular Companies in Microbiology
Table 11-3: Selected Microbiome-Based Tests
Table 11-4: Selected Companies Applying DNA/RNA Sequencing to Microbiology
Table 11-5: Selected Companies Marketing Products Addressing Emerging Infectious Disease Threats
Table 11-6: Global Microbiology Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 11-7: Global Microbiology ID/AST Market, 2022-2027 (in millions USD) (ID/AST Auto, ID/AST Panels, Blood Culture, Chromogenic Media, Rapid Microbiology; ID/AST Supplies)
Table 11-8: Global ID/AST Testing Sales Distribution by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 11-9: Global ID/AST Testing, Distribution by Systems, 2022 (%) (Panel, Auto)
Table 11-10: Selected Advanced Techniques in Positive Blood Culture
Table 11-11: Selected Infectious Disease Immunoassay Innovations
Table 11-12: Global Clinical Laboratory-Based Microbiology/Infectious Disease Immunoassay Market by Pathogen, 2022 (in $ millions) (Hepatitis, HIV, STDs, ToRCH, Respiratory, HAIs/Sepsis, Parasitology, Mycology, Lyme disease, Other, COVID-19) est.
Table 11-13: Global Laboratory-Based Microbiology/Infectious Disease Immunoassay Market Distribution (by %) by Region, 2022 (North America, Europe, Asia Pacific, RoW)
Table 11-14: Selected HIV Assays
Table 11-15: Global Rapid Immunoassay Testing Market, Sales Distribution by Pathogen, 2022 (%) (Influenza, HIV, STD, Hepatitis, Malaria, C.Difficile, E.coli, H.pylori, Home Test/OTC, Others)
Table 11-16: Global Molecular Microbiology Sales Distribution by Region, 2022 (%) (North America, Europe, Asia Pacific, RoW)
Table 11-17: Global Molecular Microbiology Market, by Pathogen/Disease Indication, 2022-2027(in $ millions) (HAI, HIV, Hepatitis, GC/Chlamydia, Respiratory, Organism ID, Mycobacteria/TB, Others; Blood Bank Screening)
Table 11-18: Selected Automated Molecular Test Instrument Platforms
Table 11-19: Selected Molecular Point of Care Innovations in Microbiology
Table 11-20: Innovations in Molecular POC Diagnostics for HIV
Table 11-21: Frequency of the Most Common Nosocomial Infections
Table 11-22: Selected Companies Marketing Mass Spectrometers and/or Assays for the Clinical Laboratory [CE-Marked and/or 510(k) cleared]
Table 12-1: Laboratory Screening of Blood Donations for Transfusion-Transmissible Infections, Number of Countries (Syphilis, HCV, HBV, HIV, Chagas, Malaria, HTLV I/II)
Table 12-2: Prevalence of TTIs in Blood Donations [Median (Interquartile range)], by Income Group
Table 12-3: Blood Component Usage for Selected Conditions
Table 12-4: Red Blood Cell and Platelet Use by Hospital Services (%)
Table 12-5: Impact of Alloimmunization (% of Patients Screening Positive for One or More Antibodies)
Table 12-6: Selected Blood Typing and Grouping Innovations
Table 12-7: Global Blood Typing Market, 2022-2027 (Typing) (in $ millions)
Table 12-8: Global Blood Typing Sales Distribution by Region, 2022 (%) (North America, Europe, Asia Pacific, RoW)
Table 12-9: Selected Blood Testing Innovations
Table 12-10: Global Blood Banking Diagnostics Market, 2022-2027 (Immunoassay Screen, NAT Screens) (in $ millions)
Table 12-11: Global Blood Testing Market by Geography, 2022 (%) (North America, Europe, Asia Pacific, RoW)
Table 12-12: Global Blood Testing Market by Country, 2022 (%) (United States, Canada, Germany, United Kingdom, France, Japan, China, Latin America) est.
Table 13-1: Selected Histology Lab Automation
Table 13-2: Histology Information Technology Tools
Table 13-3: Selected Advanced Histology Techniques
Table 13-4: Global HPV Test Sales Distribution by Region, 2022 (%) (North America, Europe, Asia Pacific, RoW)
Table 13-5: Selected HPV Test Innovations
Table 13-6: Global Histology/Cytology Sales by Type, 2022-2027 ($ millions) (Pap Tests, in situ hybridization, immunohistochemistry, traditional non-Pap stains, HPV, TOTAL; Digital Imaging, CTCs, Flow Cytometry)
Table 13-7: Global Histology/Cytology Sales Distribution by Region, 2022 (%) (North America, Europe, Asia Pacific, RoW)
Table 13-8: Revenues of the Major Histology Companies, 2017-2022 ($ millions, estimated)
Table 13-9: Selected Vendors of Traditional Histology Stains
Table 13-10: Primary and Secondary Prevention of Cervical Cancer, Screening Responses by Country, 2019
Table 13-11: Selected In Situ Hybridization-based Tests
Table 13-12: Selected IHC Test Innovations
Table 13-13: Major Pharmacodiagnostic Markers
Table 13-14: Selected Pharmacodiagnostic Histology Tests
Table 13-15: Selected Digital Pathology Image Capture and Viewing Solutions
Table 11-16: FDA Digital Pathology Device Review Classification During COVID-19
Table 13-17: Selected Digital Imaging Innovations
Table 13-18: Selected Innovations in CTC Technology
Table 14-1: Abbott Diagnostics Revenue History, 2017-2021 ($ million)
Table 14-2: Abbott Diagnostic Revenues by Segment, 2017-2021 ($ million) est.
Table 14-3: Agilent Revenue History Diagnostics and Genomics, 2017-2021 ($ million)
Table 14-4: Beckman Coulter Revenue History, 2017-2021 ($ million, estimated)
Table 14-5: Beckman Coulter Diagnostic Revenues by Segment, 2017-2021 ($ million) est
Table 14-5: BD Revenue History, 2017-2021 ($ million, estimated) FYE Sept 30
Table 14-6: BD Diagnostic Revenues by Segment, 2017-2021 ($ million)
Table 14-7: bioMerieux Revenue History, 2017-2021 ($ million)
Table 14-8: bioMerieux Diagnostic Revenues by Segment, 2017-2021 ($ million)
Table 14-9: Bio-Rad Revenue History, 2017-2021 ($ million, estimated)
Table 14-10: Bio-Rad Diagnostic Revenues by Segment, 2017-2021 ($ million) est
Table 14-11: Bruker Revenue History Product revenue, 2017-2021 (all; $ million)
Table 14-12: Cepheid Revenue History, 2017-2021 ($ million, clinical product sales)
Table 14-13: Danaher Revenue History, 2017-2021 ($ million, Diagnostics, estimated)
Table 14-14: DiaSorin Revenue History, 2017-2021 ($ million)
Table 14-15: Grifols Revenue History, 2017-2021 ($ million)
Table 14-16: Grifols Diagnostic Revenues by Segment, 2017-2021 ($ million)
Table 14-17: Hologic Revenue History estimated diagnostic product revenue, 2017-2021 ($ million, estimated)
Table 14-18: Hologic Diagnostic Revenues by Segment, 2017-2021 ($ million)
Table 14-19: Recent Revenue History, 2017-2021 ($ million, estimated)
Table 14-20: IL Diagnostic Revenues by Segment, 2017-2021 ($ million)
Table 14-21: Leica Revenue History, 2017-2021 ($ millions) estimated
Table 14-22: OrthoClinical Revenue History, 2017-2021 ( in $ millions, estimated)
Table 14-23: Ortho Clinical Diagnostic Revenues by Segment ($ million) est. 2021
Table 14-24: PerkinElmer Revenue History, 2017-2021 ($ million, estimated)
Table 14-25: PerkinElmer Diagnostic Revenues by Segment, 2017-2021 ($ million) est
Table 14-26: QIAGEN Revenue History, 2017-2021 ($ million)
Table 14-27: QIAGEN Diagnostic Revenues by Segment, 2017-2021 ($ million) est
Table 14-28: Quidel Revenue History, 2017-2021 ($ million)
Table 14-29: Quidel Diagnostic Revenues by Segment, 2017-2021 ($ million) est
Table 14-30: Radiometer A/S Revenue History, 2017-2021 (estimated, $ million)
Table 14-31: Roche Revenue History, 2017-2021 (in millions $)
Table 14-32: Roche Diagnostic Revenues by Segment, 2017-2021 ($ million) est
Table 14-33: Siemens Healthineers Revenue History, 2017-2021 ($ million, estimated)
Table 14-34: Siemens Healthineers Diagnostic Revenues by Segment, 2021 ($ million)
Table 14-35: Sysmex Revenue History, , 2018-2021 ($ million) FYE March 31
Table 14-36: Sysmex Diagnostic Revenues by Segment, 2018-2021 ($ million) est
Table 14-37: Thermo Fisher Revenue History, 2017-2021 (clinical diagnostics, $ million)
Table 14-38: Thermo Fisher Scientific Diagnostic Revenues by Segment, 2017-2021 ($ million)
Table 14-39: Ventana Medical Systems Revenue History, 2017-2021 ($ millions)
Table 14-40: Werfen Recent Revenue History, 2017-2021 ($ million estimated)
Table 15-1: BGI Genomics Revenue History ($ millions)
Table 15-2: Cue Health Revenue History, 2020-2021 ($ million)
Table 15-3: Dexcom Revenue History, 2017-2021 ($ million)
Table 15-4: Eiken Chemical Revenue History FYE March 31, 2017-2021 ( $millions)
Table 15-5: Exact Sciences Revenue History, 2017-2021 (in $ millions)
Table 15-6: Fulgent Revenue History, 2017-2021 ($ million)
Table 15-7: Fujirebio Diagnostics Revenue History, 2017-2021 ($ millions) FYE March 31
Table 15-8: GenMark Revenue History, 2017-2021 ($ million)
Table 15-9: Guardant Health Revenue History, 2019-2021 ($ million)
Table 15-10: Horiba Medical Revenue History, 2017-2021 (in millions USD) (medical diagnostic sales)
Table 15-11: Illumina Revenue History, 2017-2021 ($ million - not all revenues are for clinical products and services; estimated)
Table 15-12: Illumina Diagnostic Revenues by Segment, 2017-2021 ($ million) est
Table 15-13: Labcorp Revenue History, 2017-2021 ($ millions)
Table 15-14: Luminex Revenue History, 2017-2021 ($ million; company developed tests, estimated)
Table 15-15: Masimo Revenues History, 2017-2021 ($ millions)
Table 15-16: Meridian Bioscience Revenue History, 2017-2021 ($ million, estimated) FYE Sept 30
Table 15-17: Natera Revenue History, 2017-2021 ($ millions)
Table 15-18: Myriad Genetics Revenue History, 2017-2021 ($ millions) FYE June 30
Table 15-19: Nihon Kohden Revenues History, 2017-2021 ($ millions)
Table 15-20: OraSure Technologies Revenue History, 2017-2021 ($ million)
Table 15-21: Philips Revenue History, 2017-2021 ($ millions)
Table 15-22: Quest Diagnostics Revenue History, 2017-2021 ($ million)
Table 16-1: Cerus Revenue History ($ million)
Table 16-2: Quotient Limited Revenue History, 2017-2021 ($ million)
Table 17-1: EKF Diagnostics Revenue History, 2016-2021 ($ millions)
Table 17-2: Trinity Biotech Revenue History, 2017-2021 ($ millions)
Table 18-1: Biocartis Revenue History, 2017-2021 ($ million)
Table 19-1: Insulet Corp Revenue History, 2017-2021 ($ million)
Table 19-2: Medtronic Revenue History, 2017-2021 ($ million)
Table 22-1: Biomerica Revenue History, 2017-2021 ($ million)
Table 22-2: Bio-Techne Revenue History, 2017-2021 ($ million)
Table 24-1: Accelerate Diagnostics Revenue History, 2017-2021 ($ thousands)
Table 25-1: Enzo Biochem Revenue History, 2017-2021 ($ million)
Table 25-2: Fluidigm Revenue History, 2017-2021 ($ million)
Table 25-3: NanoString Revenue History, 2017-2021 ($ million)
Table 25-4: PacBio Revenue History, 2017-2021 ($ million)
Table 26-1: Chembio Diagnostics Revenue History, 2017-2021 ($ million)
Table 26-2: genedrive Revenue History, 2017-2021 (in $ millions)
Table 26-3: MedMira Revenue History, 2017-2021 ($ thousands)
Table 29-1: Aspira Women’s Health Revenue History, 2017-2021 (in $ millions)
Table 29-2: CareDx Revenue History, 2017-2021 ($ in thousands)
Table 29-3: MDxHealth Revenue History, 2017-2021 (in $ millions)
Table 29-4: OPKO Diagnostics Revenue History, 2017-2021 (in $ millions)
Table 29-5: Veracyte Revenue History, 2017-2021 (in $ millions)
